Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
NCT ID: NCT00296400
Last Updated: 2011-06-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
237 participants
INTERVENTIONAL
2006-02-28
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
NCT00296374
Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
NCT00296387
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
NCT00240318
A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome
NCT00240305
Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome
NCT00665834
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rosuvastatin
Atorvastatin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hyperlipidemia
* Urinary protein
Exclusion Criteria
* Statin intolerance
* Severe hypertension
* Diabetes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Crestor Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Avondale, Arizona, United States
Research Site
Phoenix, Arizona, United States
Research Site
Pasadena, California, United States
Research Site
Riverside, California, United States
Research Site
Clearwater, Florida, United States
Research Site
Hollywood, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Augusta, Georgia, United States
Research Site
Topeka, Kansas, United States
Research Site
Columbia, Maryland, United States
Research Site
Springfield, Massachusetts, United States
Research Site
Detroit, Michigan, United States
Research Site
Columbia, Missouri, United States
Research Site
Orchard Park, New York, United States
Research Site
Winston-Salem, North Carolina, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Columbia, South Carolina, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Richmond, Virginia, United States
Research Site
Gig Harbor, Washington, United States
Research Site
Milwaukee, Wisconsin, United States
Research Site
Curitiba, Paraná, Brazil
Research Site
São Paulo, São Paulo, Brazil
Research Site
Blagoevgrad, , Bulgaria
Research Site
Burgas, , Bulgaria
Research Site
Gabrovo, , Bulgaria
Research Site
Pleven, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Veliko Tarnovo, , Bulgaria
Research Site
Vancouver, British Columbia, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
Courtice, Ontario, Canada
Research Site
East York, Ontario, Canada
Research Site
Oakville, Ontario, Canada
Research Site
Oshawa, Ontario, Canada
Research Site
Richmond Hill, Ontario, Canada
Research Site
Scarborough Village, Ontario, Canada
Research Site
Thunder Bay, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Copenhagen, , Denmark
Research Site
Fredericia, , Denmark
Research Site
Herlev, , Denmark
Research Site
Holbæk, , Denmark
Research Site
Roskilde, , Denmark
Research Site
Viborg, , Denmark
Research Site
Berlin, , Germany
Research Site
Cloppenburg, , Germany
Research Site
Demmin, , Germany
Research Site
Düsseldorf, , Germany
Research Site
Elsenfeld, , Germany
Research Site
Göttingen, , Germany
Research Site
Hanover, , Germany
Research Site
Würzburg, , Germany
Research Site
Ajka, , Hungary
Research Site
Baja, , Hungary
Research Site
Balatonfüred, , Hungary
Research Site
Budapest, , Hungary
Research Site
Debrecen, , Hungary
Research Site
Eger, , Hungary
Research Site
Gyula, , Hungary
Research Site
Gy�r, , Hungary
Research Site
Keszthely, , Hungary
Research Site
Miskolc, , Hungary
Research Site
Nyíregyháza, , Hungary
Research Site
Szolnok, , Hungary
Research Site
Szombathely, , Hungary
Research Site
Zalaegerszeg, , Hungary
Research Site
Bergamo, BG, Italy
Research Site
Bologna, BO, Italy
Research Site
Brescia, BS, Italy
Research Site
Acireale, CT, Italy
Research Site
Foggia, FG, Italy
Research Site
Florence, FI, Italy
Research Site
Parma, PR, Italy
Research Site
Reggio Calabria, RC, Italy
Research Site
Sassari, SS, Italy
Research Site
Teramo, TE, Italy
Research Site
Torino, TO, Italy
Research Site
Castelfranco Veneto, TV, Italy
Research Site
Treviso, TV, Italy
Research Site
Mestre, VE, Italy
Research Site
Zapopan, Jalisco, Mexico
Research Site
Mexico City, Mexico City, Mexico
Research Site
D.F, Mexico, Mexico
Research Site
San Luis Potos�, Mexico, Mexico
Research Site
Cuernavaca, Morelos, Mexico
Research Site
Aguascalientes, , Mexico
Research Site
Durango, , Mexico
Research Site
Brasov, Brașov County, Romania
Research Site
Cluj-Napoca, Cluj, Romania
Research Site
Constanța, Constanța County, Romania
Research Site
Suceava, Suceava, Romania
Research Site
Timișoara, Timiș County, Romania
Research Site
Bucharest, , Romania
Research Site
Craiova, , Romania
Research Site
Iași, , Romania
Research Site
Johannesburg, Gauteng, South Africa
Research Site
Pretoria, South Africa, South Africa
Research Site
Parow, W Cape, South Africa
Research Site
Cape Town, , South Africa
Research Site
Durban, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
de Zeeuw D, Anzalone DA, Cain VA, Cressman MD, Heerspink HJ, Molitoris BA, Monyak JT, Parving HH, Remuzzi G, Sowers JR, Vidt DG. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015 Mar;3(3):181-90. doi: 10.1016/S2213-8587(14)70246-3. Epub 2015 Feb 4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PLANET II
Identifier Type: -
Identifier Source: secondary_id
D3569C00011
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.